Clinical Endpoints and Economic Parameters for Market Access and Value Creation

Anish Desai; Nilesh Mahajan; Reshmi Pillai

doi:doi:10.11648/j.ajhr.20160406.11

| Peer-Reviewed |

Clinical Endpoints and Economic Parameters for Market Access and Value Creation

Anish Desai, Nilesh Mahajan, Reshmi Pillai

Received: 24 August 2016 Accepted: 10 September 2016 Published: 15 October 2016

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

On the contrary to limited and shrinking health care budgets, there is an ever increasing pressure on healthcare system providers for more and newer resource-oriented health care along with significant cost constraints. Therefore, one should not be surprised if an effective new therapy does not find its way in practice within publicly funded health care systems. The influence of any therapy on health care costs and outcomes is essential important and is most often considered by decision makers, who have difficult task of making a choice whether already scarce resources should be invested in providing a the therapy or not. Usually simultaneous use of economic evaluation helps estimate the clinical benefits and costs of a therapy. Evidence of value for money is increasingly desired along with clinical safety and efficacy by stakeholders spread across formulary committees, reimbursement authorities, and national health-care systems etc. Today a variety of tools and techniques are available for conducting economic analyses of medical interventions, however one of the most common methodological approaches is to collect data on outcomes and costs alongside clinical trials. Moreover, the opportunities presented by utilizing real world evidence model in day-to-day clinical setup should be well utilized for capturing economic endpoints. Physicians, Patients, payers, providers and policy makers the 5 Ps are looking for awareness, adoption, affordability and accessibility the 4As. To achieve this Clinical-economic evaluation is critical for any new technology.

DOI	10.11648/j.ajhr.20160406.11
Published in	American Journal of Health Research (Volume 4, Issue 6, November 2016)
Page(s)	151-157
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Clinical Endpoints, Economic Parameters, Market Access, Value Creation, Evidence

References

[1]	Adams, MC, McCall, SM, Gray DT et al 1992, ‘Economic analysis in randomised control trials’, Medical Care, vol 30, no 3, pp 231-241.
[2]	Bulpitt, CJ & Fletcher, AC 1990, ‘Measuring costs and benefits in randomised clinical trials’, American Heart Journal, vol 118, no 3, Part 2, pp 766-771.
[3]	Drummond, MF & Davies, L 1991, ‘Economic analysis alongside clinical trials - revisiting the methodological issues’, International Journal of Technology Assessment in Health Care, pp 561-573.
[4]	Drummond, MF 1993, ‘Methodological principles for economic evaluation of pharmaceuticals’, British Journal of Medical Economics, vol 6B, pp 1-18.
[5]	Drummond MF, O’Brien, B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd edition. Oxford: Oxford University Press, 1997.
[6]	Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press. 2005.
[7]	Henry A Glick, Jalpa A Doshi, Seema S Sonnad, Daniel Polsky Economic Evaluation in Clinical Trials. 1st edition. Oxford: Oxford University Press, 2007.
[8]	Desai A, Mahajan N and Pillai R. Real world evidence: a novel step towards better patient care and outcomes. EJPMR, 2016, 3 (5), 197-205.
[9]	A K. O’Sullivan, D Thompson, M F. Drummond, and Collection of Health-Economic Data Alongside Clinical Trials: Is There a Future for Piggyback Evaluations? Value In Health 2005, Vol 8, No. 1
[10]	S Ramsey, R Willke, A Briggs, R Brown, M Buxton, A Chawla, J Cook, H Glick, B Liljas, D Petitti, S Reed.

Cite This Article

Plain Text BibTeX RIS

APA Style

Anish Desai, Nilesh Mahajan, Reshmi Pillai. (2016). Clinical Endpoints and Economic Parameters for Market Access and Value Creation. American Journal of Health Research, 4(6), 151-157. https://doi.org/10.11648/j.ajhr.20160406.11

Copy | Download

ACS Style

Anish Desai; Nilesh Mahajan; Reshmi Pillai. Clinical Endpoints and Economic Parameters for Market Access and Value Creation. Am. J. Health Res. 2016, 4(6), 151-157. doi: 10.11648/j.ajhr.20160406.11

Copy | Download

AMA Style

Anish Desai, Nilesh Mahajan, Reshmi Pillai. Clinical Endpoints and Economic Parameters for Market Access and Value Creation. Am J Health Res. 2016;4(6):151-157. doi: 10.11648/j.ajhr.20160406.11

Copy | Download

@article{10.11648/j.ajhr.20160406.11,
  author = {Anish Desai and Nilesh Mahajan and Reshmi Pillai},
  title = {Clinical Endpoints and Economic Parameters for Market Access and Value Creation},
  journal = {American Journal of Health Research},
  volume = {4},
  number = {6},
  pages = {151-157},
  doi = {10.11648/j.ajhr.20160406.11},
  url = {https://doi.org/10.11648/j.ajhr.20160406.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajhr.20160406.11},
  abstract = {On the contrary to limited and shrinking health care budgets, there is an ever increasing pressure on healthcare system providers for more and newer resource-oriented health care along with significant cost constraints. Therefore, one should not be surprised if an effective new therapy does not find its way in practice within publicly funded health care systems. The influence of any therapy on health care costs and outcomes is essential important and is most often considered by decision makers, who have difficult task of making a choice whether already scarce resources should be invested in providing a the therapy or not. Usually simultaneous use of economic evaluation helps estimate the clinical benefits and costs of a therapy. Evidence of value for money is increasingly desired along with clinical safety and efficacy by stakeholders spread across formulary committees, reimbursement authorities, and national health-care systems etc. Today a variety of tools and techniques are available for conducting economic analyses of medical interventions, however one of the most common methodological approaches is to collect data on outcomes and costs alongside clinical trials. Moreover, the opportunities presented by utilizing real world evidence model in day-to-day clinical setup should be well utilized for capturing economic endpoints. Physicians, Patients, payers, providers and policy makers the 5 Ps are looking for awareness, adoption, affordability and accessibility the 4As. To achieve this Clinical-economic evaluation is critical for any new technology.},
 year = {2016}
}

Copy | Download

TY  - JOUR
T1  - Clinical Endpoints and Economic Parameters for Market Access and Value Creation
AU  - Anish Desai
AU  - Nilesh Mahajan
AU  - Reshmi Pillai
Y1  - 2016/10/15
PY  - 2016
N1  - https://doi.org/10.11648/j.ajhr.20160406.11
DO  - 10.11648/j.ajhr.20160406.11
T2  - American Journal of Health Research
JF  - American Journal of Health Research
JO  - American Journal of Health Research
SP  - 151
EP  - 157
PB  - Science Publishing Group
SN  - 2330-8796
UR  - https://doi.org/10.11648/j.ajhr.20160406.11
AB  - On the contrary to limited and shrinking health care budgets, there is an ever increasing pressure on healthcare system providers for more and newer resource-oriented health care along with significant cost constraints. Therefore, one should not be surprised if an effective new therapy does not find its way in practice within publicly funded health care systems. The influence of any therapy on health care costs and outcomes is essential important and is most often considered by decision makers, who have difficult task of making a choice whether already scarce resources should be invested in providing a the therapy or not. Usually simultaneous use of economic evaluation helps estimate the clinical benefits and costs of a therapy. Evidence of value for money is increasingly desired along with clinical safety and efficacy by stakeholders spread across formulary committees, reimbursement authorities, and national health-care systems etc. Today a variety of tools and techniques are available for conducting economic analyses of medical interventions, however one of the most common methodological approaches is to collect data on outcomes and costs alongside clinical trials. Moreover, the opportunities presented by utilizing real world evidence model in day-to-day clinical setup should be well utilized for capturing economic endpoints. Physicians, Patients, payers, providers and policy makers the 5 Ps are looking for awareness, adoption, affordability and accessibility the 4As. To achieve this Clinical-economic evaluation is critical for any new technology.
VL  - 4
IS  - 6
ER  -

Copy | Download

Author Information

Anish Desai

Medical Affairs & Clinical Operations & Device Safety, Johnson & Johnson Medical, Mumbai, India
Nilesh Mahajan

Medical Affairs & Clinical Operations & Device Safety, Johnson & Johnson Medical, Mumbai, India
Reshmi Pillai

Medical Affairs & Clinical Operations & Device Safety, Johnson & Johnson Medical, Mumbai, India

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Anish Desai, Nilesh Mahajan, Reshmi Pillai. (2016). Clinical Endpoints and Economic Parameters for Market Access and Value Creation. American Journal of Health Research, 4(6), 151-157. https://doi.org/10.11648/j.ajhr.20160406.11

Copy | Download

ACS Style

Anish Desai; Nilesh Mahajan; Reshmi Pillai. Clinical Endpoints and Economic Parameters for Market Access and Value Creation. Am. J. Health Res. 2016, 4(6), 151-157. doi: 10.11648/j.ajhr.20160406.11

Copy | Download

AMA Style

Anish Desai, Nilesh Mahajan, Reshmi Pillai. Clinical Endpoints and Economic Parameters for Market Access and Value Creation. Am J Health Res. 2016;4(6):151-157. doi: 10.11648/j.ajhr.20160406.11

Copy | Download

@article{10.11648/j.ajhr.20160406.11,
  author = {Anish Desai and Nilesh Mahajan and Reshmi Pillai},
  title = {Clinical Endpoints and Economic Parameters for Market Access and Value Creation},
  journal = {American Journal of Health Research},
  volume = {4},
  number = {6},
  pages = {151-157},
  doi = {10.11648/j.ajhr.20160406.11},
  url = {https://doi.org/10.11648/j.ajhr.20160406.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajhr.20160406.11},
  abstract = {On the contrary to limited and shrinking health care budgets, there is an ever increasing pressure on healthcare system providers for more and newer resource-oriented health care along with significant cost constraints. Therefore, one should not be surprised if an effective new therapy does not find its way in practice within publicly funded health care systems. The influence of any therapy on health care costs and outcomes is essential important and is most often considered by decision makers, who have difficult task of making a choice whether already scarce resources should be invested in providing a the therapy or not. Usually simultaneous use of economic evaluation helps estimate the clinical benefits and costs of a therapy. Evidence of value for money is increasingly desired along with clinical safety and efficacy by stakeholders spread across formulary committees, reimbursement authorities, and national health-care systems etc. Today a variety of tools and techniques are available for conducting economic analyses of medical interventions, however one of the most common methodological approaches is to collect data on outcomes and costs alongside clinical trials. Moreover, the opportunities presented by utilizing real world evidence model in day-to-day clinical setup should be well utilized for capturing economic endpoints. Physicians, Patients, payers, providers and policy makers the 5 Ps are looking for awareness, adoption, affordability and accessibility the 4As. To achieve this Clinical-economic evaluation is critical for any new technology.},
 year = {2016}
}

Copy | Download

TY  - JOUR
T1  - Clinical Endpoints and Economic Parameters for Market Access and Value Creation
AU  - Anish Desai
AU  - Nilesh Mahajan
AU  - Reshmi Pillai
Y1  - 2016/10/15
PY  - 2016
N1  - https://doi.org/10.11648/j.ajhr.20160406.11
DO  - 10.11648/j.ajhr.20160406.11
T2  - American Journal of Health Research
JF  - American Journal of Health Research
JO  - American Journal of Health Research
SP  - 151
EP  - 157
PB  - Science Publishing Group
SN  - 2330-8796
UR  - https://doi.org/10.11648/j.ajhr.20160406.11
AB  - On the contrary to limited and shrinking health care budgets, there is an ever increasing pressure on healthcare system providers for more and newer resource-oriented health care along with significant cost constraints. Therefore, one should not be surprised if an effective new therapy does not find its way in practice within publicly funded health care systems. The influence of any therapy on health care costs and outcomes is essential important and is most often considered by decision makers, who have difficult task of making a choice whether already scarce resources should be invested in providing a the therapy or not. Usually simultaneous use of economic evaluation helps estimate the clinical benefits and costs of a therapy. Evidence of value for money is increasingly desired along with clinical safety and efficacy by stakeholders spread across formulary committees, reimbursement authorities, and national health-care systems etc. Today a variety of tools and techniques are available for conducting economic analyses of medical interventions, however one of the most common methodological approaches is to collect data on outcomes and costs alongside clinical trials. Moreover, the opportunities presented by utilizing real world evidence model in day-to-day clinical setup should be well utilized for capturing economic endpoints. Physicians, Patients, payers, providers and policy makers the 5 Ps are looking for awareness, adoption, affordability and accessibility the 4As. To achieve this Clinical-economic evaluation is critical for any new technology.
VL  - 4
IS  - 6
ER  -

Copy | Download